Sugammadex是一类称为选择性松弛剂结合剂的新药的第一个临床代表。它彻底改变了麻醉师对药物逆转的看法。Sugammadex选择性结合罗库溴铵或维库溴铵,从而逆转它们的神经肌肉阻滞作用。由于罗库溴铵或维库溴铵的1:1结合,它能够逆转任何深度的神经肌肉阻滞。到目前为止,它已被批准用于成人患者和超过2年的儿科患者。自从在欧洲获得批准以来,Japan,澳大利亚,关于其在特殊患者人群和特定疾病中的使用的进一步见解已经变得可用。由于其药效学特征,sugammadex,与罗库溴铵合用,可能有潜力取代琥珀酰胆碱作为“黄金标准”肌肉松弛剂,用于快速序列诱导。使用罗库溴铵或维库溴铵,有可能逆转他们与sugammadex的行动,神经肌肉传递受损的患者似乎是安全的,ie,神经肌肉疾病,包括重症肌无力.尚未获得长期使用sugammadex的数据。证据表明使用summadex具有经济优势,并证明其相对较高的麻醉相关药物成本是合理的,不见了。
Sugammadex is the first clinical representative of a new class of drugs called selective relaxant binding agents. It has revolutionized the way anesthesiologists think about drug reversal. Sugammadex selectively binds rocuronium or vecuronium, thereby reversing their neuromuscular blocking action. Due to its 1:1 binding of rocuronium or vecuronium, it is able to reverse any depth of neuromuscular block. So far, it has been approved for use in adult patients and for pediatric patients over 2 years. Since its approval in Europe, Japan, and Australia, further insight on its use in special patient populations and specific diseases have become available. Due to its pharmacodynamic profile, sugammadex, in combination with rocuronium, may have the potential to displace succinylcholine as the \"gold standard\" muscle relaxant for rapid sequence induction. The use of rocuronium or vecuronium, with the potential of reverse of their action with sugammadex, seems to be safe in patients with impaired neuromuscular transmission, ie, neuromuscular diseases, including myasthenia gravis. Data from long-term use of sugammadex is not yet available. Evidence suggesting an economic advantage of using sugammadex and justifying its relatively high cost for an anesthesia-related drug, is missing.